Ocrelizumab
Modify Date: 2025-09-17 20:04:38
Ocrelizumab structure
|
Common Name | Ocrelizumab | ||
|---|---|---|---|---|
| CAS Number | 637334-45-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OcrelizumabOcrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1]. |
| Name | Ocrelizumab |
|---|---|
| Synonym | More Synonyms |
| Description | Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |
| Monoclonal antibody Pro70769 |
| Pro-70769 |
| Pro70769 |
| Rhumab 2H7 |